DocMorris AG (ZRSEF) Q1 2026 Earnings Call Transcript

DocMorris reported Q1 2026 revenue growth of 10.7% year-over-year, driven by 30.4% growth in its Rx business and 63.1% growth in Digital Services. The company also grew its active customer base to 12.6 million, up 1 million year-over-year, reinforcing its shift toward a digital and AI health platform. Management highlighted continued progress toward adjusted EBITDA breakeven, which is the key strategic milestone for investors.

Analysis

The market is likely underestimating the operating leverage hidden inside the mix shift, not the headline growth rate itself. Rx acceleration plus rapid scaling of digital services creates a two-stage margin inflection: first in contribution margin from better fixed-cost absorption, then in customer lifetime value as the platform becomes a higher-frequency health habit rather than a transactional pharmacy. That matters because once repeat behavior becomes embedded, discounting becomes less necessary to defend share, which can turn apparent top-line momentum into a durable EBITDA inflection over the next 2-4 quarters.

The second-order competitive effect is on incumbents with weaker digital distribution and slower fulfillment economics. If DocMorris keeps gaining active users while improving monetization, it can pressure traditional pharmacies on convenience rather than price, forcing them into lower-margin omnichannel investments or heavier promotions. The more interesting read-through is to logistics and generic suppliers: a faster Rx cadence can tighten working-capital discipline and improve inventory turns, which should incrementally support supplier bargaining power on scale, but hurt smaller distributors that rely on broader spread capture.

The key risk is that the current narrative may be too linear: Rx growth spikes can be volatile month-to-month, and the market could punish any deceleration after a strong March/April run. EBITDA breakeven stories also tend to compress quickly if marketing spend is stepped up to preserve growth, so the next 1-2 quarters are about proof of sustainable unit economics rather than just revenue momentum. Another tail risk is regulatory or reimbursement friction, which would hit the high-frequency Rx engine before digital services can fully offset it.

Contrarian view: the stock may still be mispriced if investors are treating this as a pure growth story instead of a platform transition. The real upside is not this quarter’s growth print; it’s whether the company can convert a larger user base into recurring, higher-margin cross-sell with lower acquisition intensity. If that works, the multiple should rerate before earnings fully catch up, because the market usually prices in business-model durability ahead of absolute profitability.

Key Decisions for Investors

• Initiate a tactical long in ZRSEF on any post-call pullback over the next 1-2 weeks; target a 15-25% rebound if the market starts pricing EBITDA breakeven as credible, with downside limited to a reassessment of growth durability.
• Pair trade: long ZRSEF / short a traditional European pharmacy or lower-growth healthcare distributor basket for 2-3 months to express the digital mix-shift thesis; the trade benefits if omnichannel leaders rerate while legacy models stay under margin pressure.
• Buy upside via calls on ZRSEF with 3-6 month expiry rather than common stock if liquidity allows; the catalyst is confirmation of margin inflection in the next quarterly update, with convexity preferable given execution risk.
• Avoid chasing after a strong rally if the stock moves >10% on the print; wait for evidence that March/April momentum persists into May/June before adding, since near-term deceleration is the main reversal trigger.